(Q46922774)

26 December 2017

title

Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines (English)

1 reference

26 December 2017

author name string

Chang-Ki Min

1

1 reference

26 December 2017

Seok Lee

2

1 reference

26 December 2017

Yoo-Jin Kim

3

1 reference

26 December 2017

Ki-Seong Eom

4

1 reference

26 December 2017

Jong-Wook Lee

5

1 reference

26 December 2017

Woo-Sung Min

6

1 reference

26 December 2017

Chun-Choo Kim

7

1 reference

26 December 2017

Chul-Soo Cho

8

1 reference

26 December 2017

Gyeongsin Park

9

1 reference

26 December 2017

publication date

1 March 2006

1 reference

26 December 2017

European Journal of Haematology

published in

1 reference

26 December 2017

volume

76

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

265-268

1 reference

26 December 2017

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Possible new role for NF-kappaB in the resolution of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2437.X

10.1111/J.0902-4441.2005.T01-1-EJH2437.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16451401

1 reference

26 December 2017